David Allen Barbie

Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation

Yixiang Li, Yasmin N. Laimon, Hyeonseo Cho, Marina Vivero et autres

Lung cancer histological subtypes include lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC). Although usually distinct, rare combined LUAD/SCLC tumors occur, and LUAD can transform into SCLC as a mechanism of resistance to targeted therapies, particularly in EGFR-Mutant LUADs with RB1/TP53 …

us, cn (code pays fourni par la source)

Presenting Features and Outcomes to Standard Systemic Therapies in Patients with MTAP -Deleted Advanced Non–Small Cell Lung Cancer

Julian Huang, Mihaela D. Aldea, Kathryn W. Miller, Julia K. Rotow et autres

PURPOSE: Methylthioadenosine phosphorylase (MTAP) is deleted in 13% of NSCLC, and MTAP two-copy deleted (MTAPdel) cancer cells are vulnerable to protein arginine methyltransferase 5 inhibitors being examined in trials. Outcomes for MTAPdel NSCLC are poorly characterized. EXPERIMENTAL DESIGN: Patients with advanced MTAPdel …

us (code pays fourni par la source)

Prognostic significance of STK11, KEAP1, and NFE2L2- mutations in lung squamous cell carcinoma treated with immunotherapy with or without chemotherapy.

Sheng Liew, Mark Yungjie Jeng, Lingzhi Hong, Federica Pecci et autres

e20635 Background: Mutations in STK11 and KEAP1 are consistently associated with poor prognosis in NSCLC. In the lung squamous cell carcinoma (LSCC) subtype, KEAP1 and NFE2L2 mutations converge on constitutive activation of NRF2, a key oncogenic driver of tumor progression. Although KEAP1 …

us (code pays fourni par la source)

Integrin beta-6: Its emerging role as a therapeutic target in solid tumors

Rachel E. Sanborn, Solange Peters, David Allen Barbie

Integrins, a family of heterodimeric transmembrane receptors, mediate bidirectional intercellular communication as well as cellular communication with the extracellular matrix. Integrin beta-6 (IB6), which is formed via exclusive dimerization of the β6 subunit with the αv subunit, is expressed at low levels …

us, ch (code pays fourni par la source)

Abstract 1850: Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers.

Antja-Voy Hartley, Mustafa Al-Dulaimi, Navin R. Mahadevan, Pinar Eser et autres

Abstract TEA/TEF-domain [TEAD] inhibitors are being evaluated in clinical trials for cancers with alterations in the Hippo pathway including mesothelioma. We recently developed and showcased the potency of TEAD palmitoylation inhibitors MYF-03-69 and MYF-03-176 in mesothelioma cell lines. However, TEAD inhibition results …

us (code pays fourni par la source)

Abstract 4904: Reprogramming of the non-pathogenic E. coli surface architecture to create next-generation immune engagers for potent cancer therapies

Shaobo Yang, Anna Clara Bader, Stephanie Sendker, Ashley Hu et autres

Abstract Background: Multi-specific immune engagers show therapeutic promise but are limited by systemic toxicities (e.g., cytokine release syndrome, CRS), short half-lives, and poor infiltration into the immunosuppressive tumor microenvironment (TME). Tumor-homing bacteria offer a targeted delivery strategy capable of overcoming restricted infiltration …

us (code pays fourni par la source)

Abstract 2830: Immunomodulatory response in Dato-DXd-treated non-small cell lung cancer patient-derived organotypic tumor spheroids (pDOTS)

Satoru Yasuda, Patrick Hall Lizotte, Elena Ivanova, Zhaorong Li et autres

Abstract Background: Datopotamab deruxtecan (Dato-DXd, DATROWAY) is a TROP2-directed ADC with a highly potent Topo I inhibitor payload, which is approved for HR+ breast cancer and EGFR-mutated NSCLC in the US and is being investigated in several registrational phase 3 trials, including …

us, de, jp (code pays fourni par la source)

A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis (Adv. Funct. Mater. 28/2026)

Elena Cambria, Adriana Blazeski, Eunkyung Clare Ko, Tran Cam Thai et autres

Microfluidic Model of Fibrotic Lung Vasculature In their Research Article (10.1002/adfm.202515610), Sarah E. Shelton, Roger D. Kamm, and co-workers present a human microvascular model of lung fibrosis. This confocal projection visualizes engineered microvascular networks formed in the presence of fibroblasts derived from …

us (code pays fourni par la source)

Abstract PR002: Design of dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy to treat advanced renal cell carcinoma (RCC)

Yufei Wang, Nithyassree Murugan, Gabriella M. Kastrunes, Hsien-Chi Yuan et autres

Abstract Solid tumors hijack immune system through tumor-immune cycle. Here, we tackle multiple key steps to achieve a great therapeutic effect for clear cell renal cell carcinoma (ccRCC) treatment. Using direct stochastic optical reconstruction microscopy (dSTORM) and immunohistochemistry (IHC), we first quantified …

us (code pays fourni par la source)

A Vascular Microphysiological Model of Lung Fibrosis Reveals That Myofibroblasts and IPF Patient‐Derived Fibroblasts Impair Angiogenesis and Vasculogenesis

Elena Cambria, Adriana Blazeski, Eunkyung Clare Ko, Tran Cam Thai et autres

ABSTRACT Lung fibrosis, characterized by chronic and progressive scarring, has no cure. Its hallmarks are the accumulation of myofibroblasts and extracellular matrix, as well as vascular remodeling. The crosstalk between myofibroblasts and vasculature is poorly understood, with conflicting reports on whether angiogenesis …

us (code pays fourni par la source)

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms

Maria Davern, Cole J. Turner, Daryl Griffin, Lara Bencsics et autres

us (code pays fourni par la source)

Targeting STING to generate therapeutic anti-tumor immunity

Caroline G. Fahey, Anthony F. Cordova, Patrick C. Gedeon, David Allen Barbie

us (code pays fourni par la source)